Genetic alterations in hepatocellular carcinoma;Alterations genetiques associees au carcinome hepatocellulaire

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 1, 1997, Pages 34-44

  Böige, Valérie ^a   Laurent Puig, Pierre ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b INSTITUT CURIE   (France)

Author keywords

allelic loss; allelotype; carcinogenesis; genetic alterations; hepatocellular carcinoma; oncogene; p53; tumor suppressor gene

Indexed keywords

CARCINOGENESIS; GENETIC REGULATION; HUMAN; LIVER CELL CARCINOMA; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; CHROMOSOME ABERRATION; GENE REARRANGEMENT; GENETICS; LIVER TUMOR; MUTATION; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; CHROMOSOME ABERRATIONS; GENE REARRANGEMENT; HUMANS; LIVER NEOPLASMS; MUTATION; PROGNOSIS;

EID: 0031045978     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Laurent-Puig P, Fléjou JF. Intérêt physiopathologique et diagnostique des altérations génétiques des cancers digestifs. Gastroenterol Clin Biol 1996;20:B21-6.
2. Aihara T, Noguchi S, Sasaki Y. Nakano H, Imaoka S. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology 1994;107:1805-11.
3. Ezaki T, Kanematsu T, Okamura T, Sonoda T, Sugimachi K. DNA analysis of hepatocellular carcinoma and clinicopathologic implications. Cancer 1988;61:106-9.
4. Chiu JH, Kao HL, Wu LH, Chang HM, Lui WY. Prediction of relapse of survival after resection in human hepatomas by DNA flow cytometry. J Clin Invest 1992;89:539-45.
5. Fujimoto J, Okamoto E, Yamanaka N, Toyasaka A, Mitsunobu M. Flow cytometric DNA analysis of hepatocellular carcinoma. Cancer 1991;67:939-44.
6. Chen MF, Hwang TL, Tsao KC, Sun CF, Chen TJ. Flow cytometric DNA of hepatocellular carcinoma: preliminary report. Surgery 1991;109:455-8.
7. Thomas R, Berman J, Yetter R, Moore W, Hutchins G. Liver cell dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum Pathol 1992;23:496-503.
8. Bardi G, Johansson B, Pandis N, Heim S, Mandahl N, Andren-Sandberg J, et al. Cytogenetic findings in three primary hepatocellular carcinoma. Cancer Genet Cytogenet 1991;58:191-5.
9. Simon D, Knowles B, Weith A. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas. Oncogene 1991;6:765-70.
10. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, et al. Allelotype of colorectal cancer. Science 1989;244:207-11.
11. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, et al. Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991;51:89-93.
12. Slagle B, Zhou YI, Butel J. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinoma. Cancer Res 1991;51:49-54.
13. Konishi M, Kikushi-Yanoshita R, Tanaka K, Sato C, Tsuruta K, Maeda Y, et al. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn J Cancer 1993;84:893-9.
14. Takahashi K, Kudo J, Ishibadhi H, Hirata Y, Niho Y. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma. Hcpatology 1993;17:794-9.
15. Hsu HC, Peng SY, Lai PL, Sheu JC, Chen DS, Lin LI, et al. Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. Cancer 1994;73:42-7.
16. Nose H, Imazeki F, Ohio M, Omata O. p53 gene mutations and 17p allelie deletions in hepatocellular carcinoma from Japan. Cancer 1993;72:355-60.
17. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, et al. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992;52:5368-72.
18. Zhang W, Hirohashi S, Tsuda H, Shimosato Y, Yokota J, Terada M, et al. Frequent loss of heterozygosity on chromosome 4 and 16 in human hepatocellular carcinoma. Jpn J Cancer Res 1990;81:108-11.
19. Tsuda H, Zhang W, Shimosato Y, Yokota J, Terada M, Sugimura T, et al. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6791-4.
20. Sakai K, Nagahara H, Abe K, Obata H. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J Gastroenterol Hepatol 1992;7:288-92.
21. Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K. Accumulation of allelic loss on arms of chromosomes 13q, 16q, and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 1992;51:862-8.
22. Tsuda H, Oda T, Sakamoto M, Hirohashi S, Different pattern of chromosomal allele loss in hepatocellular carcinomas as evidence of their multifocal origin. Cancer Res 1992;52:1504-9.
23. Slagle B, Zhou YZ, Birchmeier W, Scorsone K. Deletion of the E-cadherin gene in hepatitis B virus-positive Chinese hepatocellular carcinomas. Hepatology 1993;18:757-62.
24. Fujimoto Y, Hampton L, Wirth P, Wang NJ, Xie JP, Thorgeirsson SS. Alterations of tumor suppressor genes and allelic losses in hepatocellular carcinoma in China. Cancer Res 1994;54:281-5.
25. Buetow KH. Genetic studies of human primary hepatocellular carcinoma. Prog Clin Biol Res 1992;376:155-72.
26. De Mitri MS, Pisi E, Bréchot C, Paterlini P. Low frequency of allelic loss in the cyclin A gene in human hepatocellular carcinomas: a study based on PCR. Liver 1993;13:259-61.
27. Wang HP, Rogler CE. Deletion in human chromosome arms 11p and 13q in primary hepatocellular carcinomas. Cytogenet Cell Genet 1988;48:772-8.
28. Walker GJ, Hayward NK, Falvey S, Cooksley WGE. Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res 1991;51:4367-70.
29. Kuroki T, Fujiwara Y, Nakamori S, Imaoka S, Kanematsu T, Nakamura Y. Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q. Br J Cancer 1995;72:383-5.
30. Kuroki T, Fujiwara Y, Tsuchiya E, Nakamori S, Imaoka S, Kanematsu T, et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity on chromosome arm 1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosom Cancer 1995;13:163-7.
31. Yen S, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res 1994;54:4188-92.
32. De Souza A, Hankins G, Washington M, Fine R, Orton T, Jirtle R. Frequent loss of heterozygosity on 6q at the mannose 6 - phosphate / insulin - like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10:1725-9.
33. Nishida N, Fukuda Y, Kokuryu H, Toguchida J, Yandel D, Ikenega M, et al. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 1993;53:368-72.
34. Emi M, Fujiwara Y, Ohata H, Tsuda H, Hirohashi S, Koike M, et al. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma. Genes Chromosom Cancer 1993;7:152-7.
35. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 1994;54:231-5.
36. Ding SF, Habib NA, Dooley J, Wood C, Bowles L, Delhanty JDA. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. J Cancer 1991;64:1083-7.
37. Knudson AG. Hereditary cancer, oncogenes and antioncogenes. Cancer Res 1985;45:1437-43.
38. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
39. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutation of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31.
40. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, et al. Allelotype of breast cancer: accumulative allelc losses promote tumor progression in primary breast cancer. Cancer Res 1990;50:7184-9.
41. Wales MK, Biel M, El Deiry W. Nelkin B, Issa JP, Cavence W, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1995;1:570-7.
42. Fujiwara Y, Ohata H, Emi M, Okui K, Koyama K, Tsuchiya E, et al. A 3-Mb physical map of the chromosome region 8p21.3-p22, including a 600-kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer and non-small cell lung cancer. Genes Chromosom Cancer 1994;10:7-14.
43. Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, et al. Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. Oncogene 1995;10:891-5.
44. Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutation of the E-cadherin gene in gynecologic cancers. Nat Genet 1994;7:98-102.
45. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
46. Kozyraki R, Scoazec JY, Fléjou JF, D'Errico A, Bedossa P, Terris B, et al. Expression of cadherins and α-catenin in primary epithelial tumors of the liver. Gastroenterology 1996;110:1137-49.
47. Wang J, Chenivesse X, Henglein B, Bréchot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990;343:555-7.
48. Pasquinelli C, Garreau F, Bougueleret L, Cariani E, Grzechik KH, Thiers V. et al. Rearrangement of a common cellular DNA domain on chromosome 4 in human primary liver tumours. J Virol 1988;62:629-32.
49. Buetow KH, Murray JC, Israel JL, London WT, Smith M, Kew M, et al. Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc Natl Acad Sci USA 1989;86:8852-6.
50. Ding SF, Delhanty JDA, Dooley JS, Bewles L, Wood CB, Habib NA. The putative tumour suppressor gene on chromosome 5q for hepatocellular carcinoma is distinct from the MCC and APC genes. Cancer Detect Prev 1993;17:405-9.
51. Mathew S, Murty V, Bosl G, Chaganti R. Loss of heterozygosity identifies multiple sizes of allelic deletions on chromosome 1 in human male germ cell tumors. Cancer Res 1994;54:6265-9.
52. Cryns V, Yi SM, Tahara H, Gaz R, Arnold A. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosom Cancer 1995;13:9-17.
53. De Souza A, Hankins G, Washington M, Orton T, Jirtle R. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-9.
54. Tsuda H, Hirohashi S, Shimosato Y, Ino Y, Yoshida T, Terada M. Low incidence of point mutation uf c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn J Cancer Res 1989;80:196-9.
55. Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 1990;50:1121-4.
56. Ogata N, Kamimura T, Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-Ras gene in human hepatocellular carcinoma. Hepatology 1990;13:31-7.
57. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K, Wolle H. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 1991;6:857-62.
58. Challen C, Guo K, Collier JD, Cavanagh D, Bassendine MF. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 1992;14:342-6.
59. Lin SY, Chen PH, Wang CK, Liu JD, Siauw CP, Chen YJ, et al. Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. Am J Clin Pathol 1993;100:686-9.
60. Leon M, Kew MC. Analysis of ras gene mutations in hepatocellular carcinoma in southern afriean blacks. Anticancer Res 1995;15:859-61.
61. Zhang XK, Huang DP, Qiu DK, Chiu JF. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors. Oncogene 1990;5:909-14.
62. Tiniakos D, Spandinos DA, Yiagnisis M, Tiniakos G. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease. Hepatogastroenterology 1993;40:37-40.
63. Jadirgar J, Nonomura A, Patil J, Thor A, Paronetto F. Ras oncogene p21 expression in hepatocellular carcinoma. J Exp Pathol 1989;4:37-46.
64. Moroy T, Marchio A, Etiemble J, Trépo C, Tiollais P, Buenda MA. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchuks. Nature 1986;324:276-80.
65. Peng SY, Lai PL, Hsu HC. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc 1993;92:866-70.
66. Fujiwara Y, Monden M, Mori T, Nakamura Y, Emi M. Frequent multiplication of lhe long arm of chromosome 8 in hepatocellular carcinoma. Cancer Res 1993;53:857-60.
67. Nasarek A, Werner M, Nolte M, Klempnauer J, Georgii A. Trisomy 1 and 8 occur frequently in hepatocellular carcinoma but not in liver cell adenoma and focal nodular hyperplasia. A fluorescence in situ hybridation study. Virchows Arch 1995;427:373-8.
68. Robinson WS. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu Rev Med 1994;45:297-323.
69. Zhang YJ, Jiang W. Chen CJ, Lee CS, Khan SM, Santella RM, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 1993;196:1010-6.
70. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991;51:5520-5.
71. Murakami Y, Hayashi K, Sekiya T. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 1991;51:3356-61.
72. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
73. Debuire B, Paterlini P, Ponlisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993;8:2303-6.
74. Scorsone KA, Zhou YZ, Butel JS, Slagle BL. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1992;52:1635-8.
75. Kress S, Jahn UR, Buchmann A, Bannasch P, Schwarz M. p53 mutations in human hepatocellular carcinomas from Germany. Cancer Res 1992;52:3220-3.
76. Shieh YSC, Nguyen C, Vocal MV, Chu HW. Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma. Int J Cancer 1993;54:558-62.
77. Hollstein MC, Wild CP, Bleicher F, Chutimataewin S, Harris CC, Srivatanakul P, et al. p53 mutations and allatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer 1993;53:51-5.
78. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 1992;52:3674-8.
79. Sheu JC, Huang GT, Lee PH, Chung JC, Chou HC, Lai MY, et al. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 1992;52:6098-100.
80. Buetow KH, Sheffield VC, Zhu M, Zhou T, Shen FM, Hiro O, et al. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Nail Acad Sci USA 1992;89:9622-6.
81. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52:6358-64.
82. Li D, Cao Y, He L, Wang NJ, Gu JR. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 1993;14:169-73.
83. Challen C, Lunec J, Warren W, Collier J, Bassendine HF. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology 1992;16:1362-6.
84. Lai MY, Chang HC, Li HP, Ku CK, Chen PJ, Sheu JC, et al. Splicing mutations of the p53 gene in human hepatocellular carcinoma. Cancer Res 1993;53:1653-6.
85. Hosono S, Chou MJ, Lee CS, Shih C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene 1993;8:491-6.
86. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993;14:987-92.
87. Tanaka S, Tob Y, Adachi E, Matsumata T, Mori R, Sugimachi K, et al. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 1993;53:2884-7.
88. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 1993;7:1407-13.
89. Ng IOL, Chung LP, Tsang SWY, Lam CL, Lai ECS, Fan ST, et al. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 1994;9:985-90.
90. Unsal H, Yakicier C, Marcais C, Kew M, Volkmann M, Zentgraf H, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994;91:822-6.
91. Volkmann M, Hofmann WJ, Muller M, Räth U, Otto G, Zentgraf H, et al. p53 Overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994;9:195-204.
92. Hsu HC, Peng SY, Lai PL, Chu JS, Lee PH. Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int J Oncol 1994;4:1341-7.
93. Ng IO, Srivastava G, Chung LP, Tsang SW, Ng MM. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellulur carcinomas in Hong Kong Chinese people. Cancer 1994;74:30-7.
94. Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994;83:197-200.
95. Oda H, Nakatsuru Y, Imai Y, Sugimura H, Ishikawa T. A mutational hot spot in the p53 gene is associated with hepatoblastomas. Int J Cancer 1995;60:786-90.
96. Laurent-Puig P, Fléjou JF, Fabre M, Bedossa P, Belghiti J. Gayral F, et al. Overexpression of p53: a rare event in a large series of white patients with hepatocellular carcinoma. Hepatology 1992;16:1171-5.
97. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 1993;53:4691-4.
98. D'Errico A, Grigioni WF, Fiorentino M, Baccarini P, Grazi GL, Mancini AM. Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma. Pathol Int 1994;44:682-7.
99. Wee A, Teh M, Raju GC. p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection. J Clin Pathol 1995;48:236-8.
100. Livni N, Eid A, Ilan Y, Rivkind A, Rosenmann E, Blendis L, et al. p53 expression in patients with and without hepatocellular carcinoma. Cancer 1995;75:2420-6.
101. Bourdon JC, D'Errico A, Paterlini P, Grigioni W, May E, Debuire B. p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 1995;108:1176-82.
102. Cesarman E, Inghiram G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutation in anaplastic large cell lymphoma. Am J Pathol 1993;3:845-56.
103. Rubio MP, Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993;53:3465-7.
104. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis Bx antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-17.
105. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-20.
106. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994;91:2230-4.
107. Ueda H, Ullrich S, Gangemi D, Kappel C, Ngo L, Feitelson M, et al. Functional inactivation but not mutation of p53 causes liver cancer. Nat Genet 1995;9:41-7.
108. Ludow JW. Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and P53. FASEB J 1993;7:866-71.
109. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-60.
110. Zhang X, Xu HJ, Murakami Y, Sachse R, Yashima K, Hirohashi S. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res 1994;54:4177-82.
111. Eshleman J, Markowitz S. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995;7:83-9.
112. Han HJ, Yanagisawa A, Kato Y, Park JG, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993;53:5087-9.
113. MacDonald GA, Greenson JK, Saito K, Appelman HD, Boland CR. Loss of the DNA mismatch repair genes hMSH2 and/or KMLH1 is an early event in hepatic carcinogenesis (abstract). Hepatology 1995;22:219A.
114. Kim DW, Suzuki R, Harada T, Saito I, Miyamura T. Transsuppression of gene expression by hepatitis C viral core protein. Jpn J Med Sci Biol 1994;47:211-20.
115. Bréchot C, Pourcel C, Louis A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA in human hepatocellular carcinoma. Nature 1980;286:533-5.
116. Rogler CE. Recent advances in hepatitis B viruses and hepatocellular carcinoma. Cancer Cell 1990;2:366-70.
117. Henderson AS, Riply S, Hino O, Rogler CE. Identification of a chromosomal aberration associated with hepatitis B DNA integration site in human cells. Cancer Genet Cylogenet 1988;30:269-75.
118. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992;15:948-63.
119. Shaul Y, Garcia PD, Schonberg S, Rutter WJ. Integration of hepatitis B virus DNA in chromosome specific satellite sequences. J Virol 1989;63:731-4.
120. Brand N, Petkovich M, Krust A, Chambon P, DeThé H, Marchio A. et al. Identification of a second human retinoic acid receptor. Nature 1988;332:850-3.
121. Zhang XK, Egan JO, Huang D, Sun ZL, Chien VK, Chiu JF. Hepatitis B virus DNA integration and expression of an erb B-like gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1992;188:344-51.
122. Graef E, Caselmann WH, Wells J, Koshy R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 1994;9:81-7.
123. Tsei DJ, Chen PJ, Lai MY, Chen DS, Yang CS, Chen JY, et al. Inverse polymerase chain reaction for cloning cellular sequences adjacent to integrated hepatitis B virus DNA in hepatocellular carcinoma. J Virol Methods 1994;49:269-84.
124. Rogler CE, Sherman M, Su CY, Shafritz DA, Summers J, Shows TB, et al. Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. Science 1985;230:319-22.
125. Ding SF, Habib NA, Dooley J, Wood C, Bewles L, Delhanty JDA. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. Br J Cancer 1991;64:1083-7.
126. Mc Entee GP, Balls KA, Katzmann JA, Ilstrup DM, Nagorney DM. Relationship of nuclear DNA content to clinical and pathologic findings in patients with primary hepatic malignancy. Surgery 1992;111:376-9.
127. Nagasue N, Yamanoi A, Takemoto Y, Kimoto T, Uchida M, Chang YC, et al. Comparison between diploid and aneuploid hepatocellular carcinoma: a flow cytometric study. Br J Surg 1992;79:667-70.
128. Ding SF, Delhanty JDA, Bowles L, Dooley JS, Wood CB, Habib NA. Infrequent chromosome allele loss in fibrolamellar carcinoma. Br J Cancer 1993;67:244-6.
129. Ding SF, Carillo A, Dooley JS, Delhanty JDA, Bowles L, Della Serre G, et al. Multiple allelic losses in sarcomatoid liver carcinoma. Int Commun Hepatol 1993;1:295-301.
130. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-41.
131. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
132. Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K. The clinical significance of p53 gene mutation in hepatocellular carcinoma from Japan. Hepatology 1995;22: 1702-7.